- Target disease: HAT
- Main partners (since project start): Anacor Pharmaceuticals Inc, USA; Advinus Therapeutics Ltd, India; Avista Pharma (formerly SCYNEXIS), USA; Cardiabase, France; Creapharm, France; Eurofins-Optimed, France; HAT Platform; Institute of Tropical Medicine, Antwerp, Belgium; Institut de Recherche pour le Développement, France; Institut National de Recherche Biomédicale, DRC; Luxembourg Institute of Health, Luxembourg; National Trypanosomiasis Control Programme, DRC; Patheon, UK; PhinC, France; RCTs, France; SCYNEXIS Inc, USA; SGS, France; Swiss Tropical and Public Health Institute, Switzerland; Theradis Pharma, France.
- Project start: January 2010
- Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Norwegian Government, Norway; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; BBVA Foundation, Spain; Other private foundations and individuals.
Acoziborole was selected as a pre-clinical candidate for g-HAT in late 2009. This resulted from DNDi’s own lead optimization project starting with an initial hit identified in the Anacor chemical library. In 2012, it became DNDi’s first new chemical entity resulting from its own lead optimization programme to enter clinical development. Acoziborole is expected to be administered directly at home.
A pivotal Phase II/III trial started in the last quarter of 2016. Seven study sites – Katanda, Isangi, Dipumba, Ngandajika, Masi Manimba, Kwamouth, and Bolobo – were initiated in Democratic Republic of Congo (DRC). Eleven patients (out of a target 350) had been recruited by the end of 2016.
Last update: August 2017